Comprehensive Genome Profiling in Patients With Metastatic Non-Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung Trial.
Fabrice BarlesiPascale TomasiniMaryam KarimiStefan MichielsJudith RaimbourgCatherine DanielHenri JanicotAnne MadroszykClarisse Audigier-ValetteElisabeth QuoixJulien MazieresDenis Moro-SibilotEric DansinOlivier MolinierHugues MorelEric PichonAlexis B CortotJosiane OttoFrançois ChomyPierre-Jean SouquetNicolas CloarecEtienne Giroux-LeprieurIvan BiècheLudovic LacroixSandrine BoyaultValerie AttignonIsabelle SoubeyranAlain MorelAlicia Tran-DienAlexandra JacquetFilippo Gustavo Dall'OlioMarta JimenezJean-Charles SoriaBenjamin BessePublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
Molecular profiling can feasibly be implemented to guide treatment choice for the maintenance strategy in EGFR/ALK wt NSCLC; in this study it did not lead to substantial treatment benefits beyond durvalumab for PD-L1 ≥ 1 patients.
Keyphrases
- phase ii
- open label
- clinical trial
- phase iii
- small cell lung cancer
- double blind
- end stage renal disease
- placebo controlled
- newly diagnosed
- ejection fraction
- single cell
- study protocol
- chronic kidney disease
- advanced non small cell lung cancer
- randomized controlled trial
- prognostic factors
- epidermal growth factor receptor
- genome wide
- combination therapy
- peritoneal dialysis
- patient reported outcomes
- replacement therapy
- tyrosine kinase
- smoking cessation